Cargando…

A Novel Thienopyrimidine Analog, TPH104, Mediates Immunogenic Cell Death in Triple-Negative Breast Cancer Cells

SIMPLE SUMMARY: Triple-negative breast cancer (TNBC) is the most lethal and aggressive subtype of breast cancer that lacks an estrogen receptor, the progesterone receptor and the human epidermal growth factor receptor 2 (HER2), making it unsuitable for hormonal- or HER2-based therapy. TNBC is known...

Descripción completa

Detalles Bibliográficos
Autores principales: Tukaramrao, Diwakar Bastihalli, Malla, Saloni, Saraiya, Siddharth, Hanely, Ross Allen, Ray, Aniruddha, Kumari, Shikha, Raman, Dayanidhi, Tiwari, Amit K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074041/
https://www.ncbi.nlm.nih.gov/pubmed/33919653
http://dx.doi.org/10.3390/cancers13081954
_version_ 1783684266005102592
author Tukaramrao, Diwakar Bastihalli
Malla, Saloni
Saraiya, Siddharth
Hanely, Ross Allen
Ray, Aniruddha
Kumari, Shikha
Raman, Dayanidhi
Tiwari, Amit K.
author_facet Tukaramrao, Diwakar Bastihalli
Malla, Saloni
Saraiya, Siddharth
Hanely, Ross Allen
Ray, Aniruddha
Kumari, Shikha
Raman, Dayanidhi
Tiwari, Amit K.
author_sort Tukaramrao, Diwakar Bastihalli
collection PubMed
description SIMPLE SUMMARY: Triple-negative breast cancer (TNBC) is the most lethal and aggressive subtype of breast cancer that lacks an estrogen receptor, the progesterone receptor and the human epidermal growth factor receptor 2 (HER2), making it unsuitable for hormonal- or HER2-based therapy. TNBC is known for its higher relapse rate, poorer prognosis and higher rate of metastasis compared to non-TNBC because although patients initially respond to chemotherapy that kills cancer cells through a form of programmed cell death called apoptosis, they later develop chemoresistance and stop responding to the treatment, accounting for one fourth of all breast cancer deaths. In this study, we report a novel compound, TPH104, that elicits a unique, non-apoptotic cell death in TNBC cells. Upon treatment with TPH104, TNBC cells swell and burst, releasing immunogenic markers that alert and activate the immune system to further recognize and attack the neighboring breast cancer cells. ABSTRACT: Enhancing the tumor immunogenic microenvironment has been suggested to circumvent triple-negative breast cancer (TNBC) resistance and increase the efficacy of conventional chemotherapy. Here, we report a novel chemotherapeutic compound, TPH104, which induces immunogenic cell death in the TNBC cell line MDA-MB-231, by increasing the stimulatory capacity of dendritic cells (DCs), with an IC(50) value of 140 nM. TPH104 (5 µM) significantly increased ATP levels in the supernatant and mobilized intracellular calreticulin to the plasma membrane in MDA-MB-231 cells, compared to cells incubated with the vehicle. Incubating MDA-MB-231 cells for 12 h with TPH104 (1–5 µM) significantly increased TNF-α mRNA levels. The supernatants of dying MDAMB-231 cells incubated with TPH104 increased mouse bone marrow-derived DC maturation, the expression of MHC-II and CD86 and the mRNA expression of TNF-α, IL-6 and IL-12. Overall, these results indicate that TPH104 induces immunogenic cell death in TNBC cells, in part, by activating DCs.
format Online
Article
Text
id pubmed-8074041
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80740412021-04-27 A Novel Thienopyrimidine Analog, TPH104, Mediates Immunogenic Cell Death in Triple-Negative Breast Cancer Cells Tukaramrao, Diwakar Bastihalli Malla, Saloni Saraiya, Siddharth Hanely, Ross Allen Ray, Aniruddha Kumari, Shikha Raman, Dayanidhi Tiwari, Amit K. Cancers (Basel) Article SIMPLE SUMMARY: Triple-negative breast cancer (TNBC) is the most lethal and aggressive subtype of breast cancer that lacks an estrogen receptor, the progesterone receptor and the human epidermal growth factor receptor 2 (HER2), making it unsuitable for hormonal- or HER2-based therapy. TNBC is known for its higher relapse rate, poorer prognosis and higher rate of metastasis compared to non-TNBC because although patients initially respond to chemotherapy that kills cancer cells through a form of programmed cell death called apoptosis, they later develop chemoresistance and stop responding to the treatment, accounting for one fourth of all breast cancer deaths. In this study, we report a novel compound, TPH104, that elicits a unique, non-apoptotic cell death in TNBC cells. Upon treatment with TPH104, TNBC cells swell and burst, releasing immunogenic markers that alert and activate the immune system to further recognize and attack the neighboring breast cancer cells. ABSTRACT: Enhancing the tumor immunogenic microenvironment has been suggested to circumvent triple-negative breast cancer (TNBC) resistance and increase the efficacy of conventional chemotherapy. Here, we report a novel chemotherapeutic compound, TPH104, which induces immunogenic cell death in the TNBC cell line MDA-MB-231, by increasing the stimulatory capacity of dendritic cells (DCs), with an IC(50) value of 140 nM. TPH104 (5 µM) significantly increased ATP levels in the supernatant and mobilized intracellular calreticulin to the plasma membrane in MDA-MB-231 cells, compared to cells incubated with the vehicle. Incubating MDA-MB-231 cells for 12 h with TPH104 (1–5 µM) significantly increased TNF-α mRNA levels. The supernatants of dying MDAMB-231 cells incubated with TPH104 increased mouse bone marrow-derived DC maturation, the expression of MHC-II and CD86 and the mRNA expression of TNF-α, IL-6 and IL-12. Overall, these results indicate that TPH104 induces immunogenic cell death in TNBC cells, in part, by activating DCs. MDPI 2021-04-18 /pmc/articles/PMC8074041/ /pubmed/33919653 http://dx.doi.org/10.3390/cancers13081954 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tukaramrao, Diwakar Bastihalli
Malla, Saloni
Saraiya, Siddharth
Hanely, Ross Allen
Ray, Aniruddha
Kumari, Shikha
Raman, Dayanidhi
Tiwari, Amit K.
A Novel Thienopyrimidine Analog, TPH104, Mediates Immunogenic Cell Death in Triple-Negative Breast Cancer Cells
title A Novel Thienopyrimidine Analog, TPH104, Mediates Immunogenic Cell Death in Triple-Negative Breast Cancer Cells
title_full A Novel Thienopyrimidine Analog, TPH104, Mediates Immunogenic Cell Death in Triple-Negative Breast Cancer Cells
title_fullStr A Novel Thienopyrimidine Analog, TPH104, Mediates Immunogenic Cell Death in Triple-Negative Breast Cancer Cells
title_full_unstemmed A Novel Thienopyrimidine Analog, TPH104, Mediates Immunogenic Cell Death in Triple-Negative Breast Cancer Cells
title_short A Novel Thienopyrimidine Analog, TPH104, Mediates Immunogenic Cell Death in Triple-Negative Breast Cancer Cells
title_sort novel thienopyrimidine analog, tph104, mediates immunogenic cell death in triple-negative breast cancer cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074041/
https://www.ncbi.nlm.nih.gov/pubmed/33919653
http://dx.doi.org/10.3390/cancers13081954
work_keys_str_mv AT tukaramraodiwakarbastihalli anovelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells
AT mallasaloni anovelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells
AT saraiyasiddharth anovelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells
AT hanelyrossallen anovelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells
AT rayaniruddha anovelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells
AT kumarishikha anovelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells
AT ramandayanidhi anovelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells
AT tiwariamitk anovelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells
AT tukaramraodiwakarbastihalli novelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells
AT mallasaloni novelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells
AT saraiyasiddharth novelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells
AT hanelyrossallen novelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells
AT rayaniruddha novelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells
AT kumarishikha novelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells
AT ramandayanidhi novelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells
AT tiwariamitk novelthienopyrimidineanalogtph104mediatesimmunogeniccelldeathintriplenegativebreastcancercells